1. Predictors of Clinical Progression in HIV-1-Infected Adults Initiating Combination Antiretroviral Therapy with Advanced Disease in the Asia-Pacific Region
- Author
-
H. Byakwaga MBChB, PhD, K. Petoumenos BSc, MA, MPH, PhD, J. Ananworanich MD, PhD, F. Zhang MD, M. A. Boyd MD, FRACP, T. Sirisanthana MD, P. C. K. Li MD, MBBS, C. Lee MD, MBBS, C. V. Mean MD, V. Saphonn MD, PhD, S. F. S. Omar MD, MBBS, S. Pujari MD, P. Phanuphak MD, PhD, P. L. Lim MD, MPH, FAMS, N. Kumarasamy MD, MBBS, PhD, Y. M. A. Chen MD, MS, ScD, T. P. Merati MD, PhD, S. Sungkanuparph MD, R. Ditangco MD, S. Oka MD, PhD, G. Tau MD, J. Zhou BMed, MPH, PhD, M. G. Law MA, MSc, PhD, and S. Emery BSc, PhD
- Subjects
Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
The majority of HIV-infected patients in developing countries commences combination antiretroviral therapy (cART) with advanced disease. We examined predictors of disease progression in patients initiating cART with CD4 count ≤200 cells/mm 3 in the TREAT Asia HIV Observational Database. The main outcome measure was progression to either an AIDS-defining illness or death occurring 6 months after initiation of cART. We used survival analysis methods. A total of 1255 patients contributed 2696 person years of follow-up; 73 were diagnosed with AIDS and 9 died. The rate of progression to the combined end point was 3.0 per 100 person years. The factors significantly associated with a higher risk of disease progression were Indian ethnicity, infection through intravenous drug use, lower CD4 count, and hemoglobin ≤130 g/dL at 6 months. In conclusion, measurements of CD4 count and hemoglobin at month 6 may be useful for early identification of disease progression in resource-limited settings.
- Published
- 2013
- Full Text
- View/download PDF